A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2023-04-16
AEs
4
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-05 (study day 98); relationship: N; serious criteria: hospitalization
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 116); relationship: not assessed
moderate
assessed
Grade 2 Neutropenia — outcome: UNKNOWN; onset 2024-04-18 (study day 355); relationship: not assessed
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-09-03 (study day 493); relationship: not assessed
Data queries
No data queries.